RESUMO
The purpose of this publication is to review the data on European neutrontherapy facilities in the treatment of soft tissue sarcoma. Data on 1171 patients treated at 11 centers were analyzed. Neutrontherapy was of advantage especially for patients with primary radiotherapy of inoperable tumors, and those with macroscopic disease after surgery. Local control was about 50% in these groups. Results for postoperative neutrontherapy after R0 and R1 resection were similar to those for photon therapy. The incidence of late side effects was considerable. This was influenced by the fact that most patients were treated with first-generation machines.
Assuntos
Nêutrons Rápidos , Radioterapia de Alta Energia , Sarcoma/radioterapia , Neoplasias de Tecidos Moles/radioterapia , Intervalo Livre de Doença , Europa (Continente) , Humanos , Estudos Longitudinais , Estadiamento de Neoplasias , Fótons , Dosagem Radioterapêutica , Radioterapia de Alta Energia/efeitos adversos , Radioterapia de Alta Energia/métodos , Sarcoma/mortalidade , Sarcoma/patologia , Neoplasias de Tecidos Moles/mortalidade , Neoplasias de Tecidos Moles/patologiaRESUMO
From 1975-1994, 221 adult patients with a total of 232 radiation sites for soft tissue sarcomas were irradiated with fast neutrons with a mean energy of 6.2 MeV in Berlin-Buch/Dresden-Rossendorf. The tumour dose ranged between 6 and 12 Gy and was limited by the low dose penetration of the neutron beam. A local control rate of 66% was obtained. The local control was affected by the tumour differentiation, residual status and histological subtype. Severe fibrosis of the subcutaneous tissues occurred in 40% usually after 2 years. No serious general side effects occurred. To optimize neutron therapy, a high energy clinically-based cyclotron with a fully rotational gantry and a multileaf collimator should be utilized. It seems that patients with locally advanced and well differentiated sarcomas can benefit from this therapy.
Assuntos
Nêutrons Rápidos , Radioterapia de Alta Energia , Sarcoma/radioterapia , Neoplasias de Tecidos Moles/radioterapia , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Ciclotrons , Alemanha , Humanos , Estudos Longitudinais , Pessoa de Meia-Idade , Metástase Neoplásica , Estadiamento de Neoplasias , Garantia da Qualidade dos Cuidados de Saúde , Dosagem Radioterapêutica , Radioterapia de Alta Energia/instrumentação , Radioterapia de Alta Energia/métodos , Sarcoma/mortalidade , Sarcoma/patologia , Neoplasias de Tecidos Moles/mortalidade , Neoplasias de Tecidos Moles/patologiaRESUMO
Evacuolated mesophyll protoplasts from oat (Avena sativa L.) were fractionated by a membrane-filtration technique. This method of rapid quenching of metabolic reactions permitted estimation of the in-vivo pools of fructose 2,6-bisphosphate (Fru2,6bisP) in the cytosol, chloroplasts and mitochondria. Vacuolar Fru2,6bisP was calculated as the difference between control protoplasts and evacuolated ones. The results indicate that Fru2,6bisP is exclusively cytosol-located in oat mesophyll protoplasts. Assuming a cytosolic volume of about 2 pl per evacuolated protoplast, the cytosolic concentration there was 11 µM if protoplasts were in darkness. Illumination of either control or evacuolated protoplasts resulted in a significant decrease in the Fru2,6bisP content within 5 min.
